| 75th Annual Regeneron International Science and Engineering Fair Awards Teen Scientists from Around the World More Than $9 Million in 2025 Competition |
Adam Kovalčík , 19, receives $100,000 Top Award for his development of a medicine that can stop viruses from copying genes and controlling infections at the world's largest pre-college STEM competition in Columbus, Ohio |
globenewswire.com |
2025-05-16 15:24:00 |
Czytaj oryginał (ang.) |
| Regeneron Prevails over Amgen in Antitrust PCSK9 Lawsuit Protecting Biotech Innovation and Patient Access to Life-Saving Treatments |
Federal court jury found Amgen liable for violating antitrust and tort laws by using cross-therapeutic bundled rebates to prevent Praluent ® (alirocumab) from competing in the market |
globenewswire.com |
2025-05-15 18:02:00 |
Czytaj oryginał (ang.) |
| Big Dippers: 3 Stocks Near 1-Year Lows That Could Surge in 2025 |
As of mid-May 2025, the S&P 500 has turned positive year-to-date (YTD) for the first time in many weeks. Stocks across multiple sectors have broadly recovered from the jolt of tariff news and other volatility throughout April. |
marketbeat.com |
2025-05-15 11:54:21 |
Czytaj oryginał (ang.) |
| Pharma Stock Regeneron Is a Buy, Says Citi. But Be Cautious on AbbVie, Merck. |
Uncertainty around pharma tariffs on and pricing policies under the Trump has much of the sector guessing what will happen next. |
barrons.com |
2025-05-14 13:55:00 |
Czytaj oryginał (ang.) |
| Regeneron Pharmaceuticals, Inc. (REGN) BofA Securities 2025 Healthcare Conference (Transcript) |
Regeneron Pharmaceuticals, Inc. |
seekingalpha.com |
2025-05-13 19:43:01 |
Czytaj oryginał (ang.) |
| Best Biotech Stocks to Buy in 2025 |
The bear market induced by the Federal Reserve's monetary tightening officially ended in 2023, but it seems no one remembered to tell the biotech sector. |
marketbeat.com |
2025-05-13 12:10:10 |
Czytaj oryginał (ang.) |
| Regeneron Continues To Regenerate Its Drug Pipeline, While Keeping Leverage Down |
Regeneron Pharmaceuticals gets a buy rating today, agreeing with the Wall St consensus. Impressive are its drug discovery pipeline across several clinical segments, profit margins, and low Debt/Equity ratio. The firm just started paying dividends in February, so still lacks dividend growth data long-term. |
seekingalpha.com |
2025-05-12 16:35:14 |
Czytaj oryginał (ang.) |
| Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet |
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up to ten time more in some cases) than in other countries due to, e.g., R&D costs, direct-to-consumer marketing, and pharmacy benefit managers. Despite Trump's aggressive stance, Pharma stocks have risen in trading today, suggesting investors believe negotiations will soften his initial hardline approach. |
seekingalpha.com |
2025-05-12 16:30:03 |
Czytaj oryginał (ang.) |
| Landmark Science Makes RWE Services for Biopharma Industry a Boutique Experience |
LOS ANGELES, May 2, 2025 /PRNewswire/ -- Landmark Science, a premier provider of real-world evidence (RWE) solutions, is redefining industry standards with its white-glove, high-touch approach to evidence generation. With long-standing roots in biopharma, Landmark Science bridges the gap between vendors and biopharma, delivering agile and efficient solutions uniquely tailored to clients. This hand-held approach through and through helps clients avoid typical red tape situations that can delay or halt critical evidence generation to swiftly transform evidence into insights on patient care, access, and outcomes. Landmark Science founder and CEO, Shivani Aggarwal, PhD, MS, brings 15 years of experience in RWE and clinical trials from her time at leading life science companies Amgen, Regeneron, and IQVIA. With deep scientific acumen and a strong track record in evidence generation, Shivani Aggarwal drives Landmark Science's strategic vision, spearheading the delivery of innovative, data-driven solutions to help patients. "Our approach goes beyond traditional evidence generation—we partner closely with our clients to provide tailored, high-touch support that meets their unique needs," says Shivani Aggarwal. "By combining deep industry expertise with cutting-edge methodologies, we empower biopharma organizations with impactful insights that drive innovation and regulatory success at exceptional speed." With a team of seasoned epidemiologists and advanced statistical programmers, Landmark Science offers bespoke solutions with a comprehensive suite of services, including data landscaping, full-scale RWE studies, and advanced analytics. Landmark Science brings unparalleled expertise to some of the most complex therapeutic areas and offers pan-therapeutic solutions to provide invaluable support across various disease areas including hematology, oncology, immunology, and rare disease. The company leverages its extensive experience to help clients successfully navigate the rapidly evolving RWE landscape. As the demand for high-quality, real-world evidence grows, Landmark Science stands at the forefront, ensuring its clients receive rigorous scientific insights and the highest personalized service. About Landmark Science, Inc. Landmark Science, Inc. is a premier life science research organization providing real-world evidence and health outcomes research solutions. The company provides a comprehensive suite of services enabling the use of RWE in drug development. Landmark Science's team of experts deliver RWE for clinical program strategy, health economics, commercial, market access, and regulators and payors to meet diverse needs efficiently. Specialties include complex study designs used to support regulatory submissions, therapeutic area expertise, and data landscaping. To learn more, please visit www.landmarkscience.com or contact [email protected]. Media Contact:Landmark Science[email protected]+1 (424) 535-3011https://landmarkscience.com/ |
https://www.prnewswire.com |
2025-05-02 14:04:00 |
Czytaj oryginał (ang.) |
| Regeneron to Highlight Advances at ASCO with Phase 3 Adjuvant Libtayo® (cemiplimab) CSCC Updates and Promising Early Blood Cancer Data with Linvoseltamab Combination |
18 presentations across five cancer types include new insights on the potential of checkpoint inhibitors and bispecific antibodies 18 presentations across five cancer types include new insights on the potential of checkpoint inhibitors and bispecific antibodies |
globenewswire.com |
2025-05-01 13:30:00 |
Czytaj oryginał (ang.) |
| Dupixent® (dupilumab) Data Presented at ATS Reinforce Impact of Targeting Key Type 2 Inflammation Drivers to Improve Outcomes for Chronic Respiratory Diseases |
24 abstracts, including 1 oral presentation and 4 late-breaking posters on Dupixent, to showcase new clinical and real-world analyses in chronic obstructive pulmonary disease (COPD) and asthma |
globenewswire.com |
2025-05-01 13:00:00 |
Czytaj oryginał (ang.) |
| Regeneron Pharma Margins Tighten As Competition Grows, Stock Slides |
On Tuesday, Regeneron Pharmaceuticals Inc REGN reported first-quarter adjusted earnings per share of $8.22, down 14% year-over-year, missing the consensus of $8.82. |
benzinga.com |
2025-04-29 18:52:27 |
Czytaj oryginał (ang.) |
| Regeneron Stock Falls on Q1 Earnings and Sales Miss, Eylea Sales Down |
REGN reports lower-than-expected Q1 results. Lead drug Eylea sales plunge in the United States due to competition. |
zacks.com |
2025-04-29 18:25:48 |
Czytaj oryginał (ang.) |
| Regeneron Pharmaceuticals, Inc. (REGN) Q1 2025 Earnings Call Transcript |
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Q1 2025 Earnings Conference Call April 29, 2025 8:30 AM ET Company Participants Ryan Crowe - SVP, IR Leonard Schleifer - Board Co-Chair, Co-Founder, President and CEO George Yancopoulos - Board Co-Chair, Co-Founder, President and Chief Scientific Officer Marion McCourt - EVP, Commercial Chris Fenimore - EVP and CFO Conference Call Participants Tyler Van Buren - TD Cowen Alexandria Hammond - Wolfe Research Chris Schott - JPMorgan Terence Flynn - Morgan Stanley Akash Tewari - Jefferies Carter Gould - Cantor William Pickering - Bernstein Evan Seigerman - BMO Capital Markets Salveen Richter - Goldman Sachs David Risinger - Leerink Partners Operator Welcome to the Regeneron Pharmaceuticals' First Quarter 2025 Earnings Conference Call. My name is Josh, and I will be your operator for today's call. |
seekingalpha.com |
2025-04-29 16:30:00 |
Czytaj oryginał (ang.) |
| Top Stock Movers Now: Honeywell, Sherwin-Williams, Regeneron, and More |
U.S. equities were higher at midday as markets waited for further clarification from the Trump administration about possible changes in tariff policy. The Dow Jones Industrial Average rose 0.6%, and the S&P 500 and Nasdaq were up by smaller percentages. |
investopedia.com |
2025-04-29 16:06:37 |
Czytaj oryginał (ang.) |
| Regeneron (REGN) Reports Q1 Earnings: What Key Metrics Have to Say |
The headline numbers for Regeneron (REGN) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2025-04-29 14:35:55 |
Czytaj oryginał (ang.) |
| Regeneron Stock Plummets After Earnings Miss |
First-quarter adjusted earnings per share were $8.22 on revenue of $3 billion, missing analysts' expectations of EPS of $8.62 on revenue of $3.2 billion, according to FactSet. |
barrons.com |
2025-04-29 13:11:00 |
Czytaj oryginał (ang.) |
| Regeneron (REGN) Lags Q1 Earnings and Revenue Estimates |
Regeneron (REGN) came out with quarterly earnings of $8.22 per share, missing the Zacks Consensus Estimate of $8.43 per share. This compares to earnings of $9.55 per share a year ago. |
zacks.com |
2025-04-29 12:40:37 |
Czytaj oryginał (ang.) |
| Regeneron Pharma's first-quarter results miss on lower Eylea demand |
Regeneron missed Wall Street estimates for first-quarter results on Tuesday, hurt by waning demand for its blockbuster eye disease drug Eylea, sending the company's shares tumbling 7% in premarket trading. |
reuters.com |
2025-04-29 12:28:09 |
Czytaj oryginał (ang.) |
| BMO's Evan Seigerman breaks down Pfizer and Regeneron's Q1 results |
Evan David Seigerman, BMO head of healthcare research, joins 'Squawk Box' to break down Pfizer and Regeneron's quarter earnings results. |
youtube.com |
2025-04-29 12:11:18 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN |
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ:REGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. |
accessnewswire.com |
2025-02-27 22:00:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN |
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=132782&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-02-27 16:00:00 |
Czytaj oryginał (ang.) |
| Regeneron Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN |
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=132761&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-02-27 14:45:00 |
Czytaj oryginał (ang.) |
| Shareholders that lost money on Regeneron Pharmaceuticals, Inc.(REGN) should contact Levi & Korsinsky about pending Class Action - REGN |
NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) of a class action securities lawsuit. |
globenewswire.com |
2025-02-27 14:39:00 |
Czytaj oryginał (ang.) |
| REGN DEADLINE: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Regeneron Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - REGN |
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) between November 2, 2023 and October 30, 2024, both dates inclusive (the "Class Period"), of the important March 10, 2025 lead plaintiff deadline. SO WHAT: If you purchased Regeneron securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. |
accessnewswire.com |
2025-02-27 14:00:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN |
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=132730&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-02-27 12:15:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals |
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Regeneron To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Regeneron between November 2, 2023 and October 30, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Feb. 27, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) and reminds investors of the March 10, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. |
prnewswire.com |
2025-02-27 12:06:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - REGN |
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=132646&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-02-27 09:35:00 |
Czytaj oryginał (ang.) |
| Regeneron: Is It the Perfect Biotech Stock for Value and Growth? |
Regeneron Pharmaceuticals Inc. NASDAQ: REGN stock has gone relatively unnoticed from major headlines in 2024 as GLP-1 makers like Novo Nordisk A/S NYSE: NVO and Eli Lilly & Co. NYSE: LLY grabbed the spotlight. Its stock closed down 18.9% for 2024. |
marketbeat.com |
2025-02-27 09:30:29 |
Czytaj oryginał (ang.) |
| REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! |
NEW YORK CITY, NY / ACCESS Newswire / February 27, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc.. ("Regeneron" or "the Company") (NASDAQ:REGN) and certain of its officers. |
accessnewswire.com |
2025-02-27 09:00:00 |
Czytaj oryginał (ang.) |
| Shareholders that lost money on Regeneron Pharmaceuticals, Inc.(REGN) should contact The Gross Law Firm about pending Class Action - REGN |
NEW YORK , Feb. 27, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Shareholders who purchased shares of REGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. |
prnewswire.com |
2025-02-27 07:45:00 |
Czytaj oryginał (ang.) |
| Shareholders that lost money on Regeneron Pharmaceuticals, Inc.(REGN) should contact Levi & Korsinsky about pending Class Action - REGN |
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=132576&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-02-26 22:30:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN |
NEW YORK CITY, NY / ACCESS Newswire / February 26, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ:REGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. |
accessnewswire.com |
2025-02-26 22:00:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in Regeneron Lawsuit - REGN |
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=132516&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-02-26 18:30:00 |
Czytaj oryginał (ang.) |
| REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit |
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (“Regeneron” or “the Company”) (NASDAQ: REGN) and certain of its officers. |
globenewswire.com |
2025-02-26 18:00:00 |
Czytaj oryginał (ang.) |
| Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN) - March 10, 2025 Deadline to Join - Contact Levi & Korsinsky |
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=132493&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-02-26 16:00:00 |
Czytaj oryginał (ang.) |
| Lost Money on Regeneron Pharmaceuticals, Inc. (REGN)? Join Class Action Suit Seeking Recovery – Contact The Gross Law Firm |
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). |
globenewswire.com |
2025-02-26 15:29:00 |
Czytaj oryginał (ang.) |
| Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN) - March 10, 2025 Deadline to Join - Contact Levi & Korsinsky |
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=132477&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-02-26 14:45:00 |
Czytaj oryginał (ang.) |
| REGN DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Regeneron Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – REGN |
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) between November 2, 2023 and October 30, 2024, both dates inclusive (the “Class Period”), of the important March 10, 2025 lead plaintiff deadline. |
globenewswire.com |
2025-02-26 14:24:00 |
Czytaj oryginał (ang.) |
| Contact Levi & Korsinsky by March 10, 2025 Deadline to Join Class Action Against Regeneron Pharmaceuticals, Inc. (REGN) |
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=132460&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-02-26 14:15:00 |
Czytaj oryginał (ang.) |
| 1 Beaten-Down Stock That Could Soar by 50% in 2025, According to Wall Street |
Biotech giant Regeneron Pharmaceuticals (REGN 1.08%) started 2024 on a strong note and performed well through the first half of the year. However, the drugmaker has since seen its shares decline substantially due to several factors, most notably headwinds related to one of its key growth drivers (more on that later). |
fool.com |
2025-01-02 12:00:00 |
Czytaj oryginał (ang.) |
| Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results |
Investigational REGN7508 (catalytic domain) and REGN9933 (A2 domain) are being evaluated for their potential to control thrombosis while minimizing bleeding risk in a variety of patient populations and clinical settings |
globenewswire.com |
2024-12-19 09:00:00 |
Czytaj oryginał (ang.) |
| REGN's Eylea HD Shows Non-Inferiority to Eylea in Eye Disease Study |
Regeneron's phase III study evaluating Eylea HD against stand-of-care Eylea treatment meets the primary endpoint of non-inferior visual gain in RVO patients. |
zacks.com |
2024-12-18 13:21:10 |
Czytaj oryginał (ang.) |
| Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference |
TARRYTOWN, N.Y., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025. The presentation is scheduled for 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time) and may be accessed from the "Investors & Media" page of Regeneron's website at http://investor.regeneron.com/events-and-presentations.com/events-and-presentations. A replay and transcript of the webcast will be archived on the Company's website for at least 30 days. |
globenewswire.com |
2024-12-17 18:05:00 |
Czytaj oryginał (ang.) |
| Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year |
TARRYTOWN, N.Y., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced its sixth consecutive inclusion in the Dow Jones Sustainability World Index (DJSI World) and fifth consecutive inclusion in the Dow Jones Sustainability North America Index (DJSI North America). These rankings highlight the company's leadership in adopting responsible practices that drive business resilience and improve our world. |
globenewswire.com |
2024-12-16 18:30:00 |
Czytaj oryginał (ang.) |
| Regeneron Down 15.5% Year to Date: How to Play the Stock? |
REGN's lead drug, Eylea, faces a rapid decline in sales, which has impacted overall performance, even though Dupixent maintains momentum. We advise investors to wait and watch for now. |
zacks.com |
2024-12-13 12:10:18 |
Czytaj oryginał (ang.) |
| Biotech Roundup: 3 Stocks to Watch |
Most recently in the ever-growing biotech industry , investors are musing over potential changes to the sector after President-elect Donald Trump picked Martin “Marty” Makary to be the U.S. Food and Drug Administration's (FDA) next commissioner, and Robert F. |
schaeffersresearch.com |
2024-12-11 17:35:14 |
Czytaj oryginał (ang.) |
| Lost Money on Regeneron Pharmaceuticals, Inc.(REGN)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky |
NEW YORK, NY / ACCESSWIRE / December 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Regeneron Pharmaceuticals, Inc. ("Regeneron Pharmaceuticals, Inc.") (NASDAQ:REGN) concerning possible violations of federal securities laws. On October 31, 2024, Regeneron released its third quarter 2024 financial results, reporting "U.S. net sales for EYLEA HD® and EYLEA® increased 3% versus third quarter 2023 to $1.54 billion, including $392 million from EYLEA HD. |
accesswire.com |
2024-12-10 09:25:00 |
Czytaj oryginał (ang.) |
| Odronextamab ASH Presentations Underscore Impressive Potential in Earlier Lines of Treatment and Additional Types of Lymphoma |
Odronextamab monotherapy led to complete responses in all patients with previously untreated follicular lymphoma evaluable for efficacy, per initial results from the safety lead-in portion of the confirmatory Phase 3 OLYMPIA-1 trial |
globenewswire.com |
2024-12-09 19:45:00 |
Czytaj oryginał (ang.) |
| Regeneron Pharmaceuticals, Inc. Being Investigated on Behalf of Regeneron Pharmaceuticals, Inc. Investors. Contact Levi & Korsinsky For Details. |
NEW YORK, NY / ACCESSWIRE / December 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Regeneron Pharmaceuticals, Inc. ("Regeneron Pharmaceuticals, Inc.") (NASDAQ:REGN) concerning possible violations of federal securities laws. On October 31, 2024, Regeneron released its third quarter 2024 financial results, reporting "U.S. net sales for EYLEA HD® and EYLEA® increased 3% versus third quarter 2023 to $1.54 billion, including $392 million from EYLEA HD. |
accesswire.com |
2024-12-09 09:25:00 |
Czytaj oryginał (ang.) |
| Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab |
Head-to-head exploratory cohort of a Phase 3 trial showed first-in-class poze-cemdi combination treatment helped patients achieve and maintain greater disease control, as measured by lactate dehydrogenase (LDH) levels, compared to standard-of-care ravulizumab |
globenewswire.com |
2024-12-07 21:00:00 |
Czytaj oryginał (ang.) |
| Lost Money on Regeneron Pharmaceuticals, Inc. (REGN)? Contact Levi & Korsinsky Regarding an Ongoing Investigation |
NEW YORK, NY / ACCESSWIRE / December 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Regeneron Pharmaceuticals, Inc. ("Regeneron Pharmaceuticals, Inc.") (NASDAQ:REGN) concerning possible violations of federal securities laws. On October 31, 2024, Regeneron released its third quarter 2024 financial results, reporting "U.S. net sales for EYLEA HD® and EYLEA® increased 3% versus third quarter 2023 to $1.54 billion, including $392 million from EYLEA HD. |
accesswire.com |
2024-12-06 14:30:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors |
BENSALEM, Pa. , Dec. 6, 2024 /PRNewswire/ -- Law Offices of Howard G. |
prnewswire.com |
2024-12-06 14:00:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Reminds Shareholders of an Investigation into Regeneron Pharmaceuticals, Inc. (REGN) Regarding Potential Securities Fraud Allegations |
NEW YORK, NY / ACCESSWIRE / December 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Regeneron Pharmaceuticals, Inc. ("Regeneron Pharmaceuticals, Inc.") (NASDAQ:REGN) concerning possible violations of federal securities laws. On October 31, 2024, Regeneron released its third quarter 2024 financial results, reporting "U.S. net sales for EYLEA HD® and EYLEA® increased 3% versus third quarter 2023 to $1.54 billion, including $392 million from EYLEA HD. |
accesswire.com |
2024-12-06 09:25:00 |
Czytaj oryginał (ang.) |
| Regeneron Pharmaceuticals, Inc. (REGN) Piper Sandler 36th Annual Healthcare Conference (Transcript) |
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Piper Sandler 36th Annual Healthcare Conference Call December 5, 2024 9:30 AM ET Company Participants Ryan Crowe - Senior Vice President, Investor Relations & Strategic Analysis Chris Fenimore - Senior Vice President, Finance & Chief Financial Officer Conference Call Participants Chris Raymond - Piper Sandler Chris Raymond Okay, let's go ahead and get started. Thanks everybody for being here. |
seekingalpha.com |
2024-12-05 16:55:24 |
Czytaj oryginał (ang.) |
| REGN ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Regeneron Pharmaceuticals, Inc. Shareholders Who Lost Money |
NEW YORK, NY / ACCESSWIRE / December 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Regeneron Pharmaceuticals, Inc. ("Regeneron Pharmaceuticals, Inc.") (NASDAQ:REGN) concerning possible violations of federal securities laws. On October 31, 2024, Regeneron released its third quarter 2024 financial results, reporting "U.S. net sales for EYLEA HD® and EYLEA® increased 3% versus third quarter 2023 to $1.54 billion, including $392 million from EYLEA HD. |
accesswire.com |
2024-12-04 15:15:00 |
Czytaj oryginał (ang.) |
| Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors |
LOS ANGELES, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) investors concerning the Company's possible violations of the federal securities laws. |
globenewswire.com |
2024-12-04 15:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors |
BENSALEM, Pa., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith continues its investigation on behalf of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) investors concerning the Company's possible violations of federal securities laws. |
globenewswire.com |
2024-12-03 14:33:00 |
Czytaj oryginał (ang.) |
| Medigene Receives Milestone Payment from Regeneron Pharmaceuticals, Inc. |
Planegg/Martinsried, December 3, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, today announced a USD $1 million milestone payment from Regeneron Pharmaceuticals, Inc. was triggered. Regeneron purchased the MAGE-A4-TCR program as part of its acquisition of 2seventy bio Inc.'s pre-clinical and clinical oncology and autoimmune cell therapy pipeline, which closed in April 2024. The payment was triggered by a development milestone for a trial in China led by JW Therapeutics (also a prior collaborator of 2seventy bio, Inc.) of Regeneron's MAGE-A4 cell therapy, which contains a Medigene generated T cell receptor (TCR) targeting MAGE-A4. |
globenewswire.com |
2024-12-03 07:00:00 |
Czytaj oryginał (ang.) |
| The Law Offices of Frank R. Cruz Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors |
LOS ANGELES , Dec. 2, 2024 /PRNewswire/ -- The Law Offices of Frank R. Cruz continues its investigation of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) on behalf of investors concerning the Company's possible violations of federal securities laws. |
prnewswire.com |
2024-12-02 14:00:00 |
Czytaj oryginał (ang.) |